Table 3.

Rate and Hazard Ratio for ART eligibility

	N	Events/pyr	Rate/100pyr	Crude HR (95%CI)	Adjusted HR (95%CI)
Overall	438	205/ 631.98	32.4
Study arm
Placebo	219	110/303.8	36.21	1.0	1.0
Treatment	219	95/328.1	28.95	0.79(0.60, 1.04)	0.75 (0.57,0.99)
Sex
Female	310	143/440.4	32.5	1.0	1.0
Male	128	62/191.6	32.4	0.98 (0.73,1.33)	0.79 (0.57,1.08)
Age-group
20-29	90	49/126.2	38.8	1.0	1.0
30-39	185	82/267.1	30.7	0.80 (0.56,1.14)	0.87 (0.60,1.24)
40-49	107	49/162.3	30.2	0.78 (0.53,1.16)	0.95 (0.63,1.44)
50+	56	25/76.3	32.7	0.90 (0.56,1.46)	1.01 (0.62,1.67)
Baseline CD4
300-349	211	117/282.3	25.2	1.0	1.0
350-399	227	88/349.7	41.4	0.57 (0.43,0.75)	0.58 (0.44,0.77)
Baseline Viral load
<10 000	132	37/218.8	16.9	1.0
10 000-49 999	138	73/202.1	36.1	2.25 (1.51,3.34)	2.20 (1.47,3.29)
50 000-99 999	43	27/61.1	44.2	2.92 (1.77,4.79)	2.82 (1.70,4.68)
100 000+	125	68/149.97	45.3	3.01 (2.02,4.50)	3.17 (2.10,4.78)
Baseline Viral load
<50 000	270	110/420.9	26.1	1.0
50 000+	168	95/211.1	45.0	1.88 (1.43,2.48)

ART: antiretroviral therapy, pyr: person years, HR: hazard ratio